Evommune, Inc.
EVMN
$18.41
-$1.82-9.00%
NYSE
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -100.00% | -- | |||
| SG&A Expenses | -8.56% | 7.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.52% | -5.02% | |||
| Operating Income | -52.97% | 20.82% | |||
| Income Before Tax | 6.81% | 20.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.81% | 20.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.81% | 20.54% | |||
| EBIT | -52.97% | 20.82% | |||
| EBITDA | -54.34% | 21.38% | |||
| EPS Basic | 8.02% | 24.18% | |||
| Normalized Basic EPS | 8.02% | 21.07% | |||
| EPS Diluted | 8.02% | 24.18% | |||
| Normalized Diluted EPS | 8.02% | 21.07% | |||
| Average Basic Shares Outstanding | 1.30% | 0.68% | |||
| Average Diluted Shares Outstanding | 1.30% | 0.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||